| Literature DB >> 36119702 |
LiXia Wang1, FaPing Wang1, Chuan Yang2, FengMing Luo1.
Abstract
Background: Mycobacterium houstonense is a rapidly growing mycobacterium (RGM) that belongs to the unnamed third biovariant complex of the Mycobacterium fortuitum group, which is rarely responsible for human infection. Approximately 76% of infections caused by the M. fortuitum group occur after open fractures or skin, soft tissue, bone, or puncture wounds. To date, only a few cases of human infectious disease caused by M. houstonense have been reported worldwide. Case presentation: We present a case of a 26-year-old man with a central nervous system (CNS) infection caused by M. houstonense. The patient was transferred to our hospital because of headaches and muscle strength changes. One month prior to presentation at our hospital, the patient was diagnosed with tuberculous meningitis at the other two hospitals, but his condition did not improve after anti-tuberculous treatment, antibiotics, and anti-viral treatment before admission to our hospital. Lumbar puncture was performed at both previous hospitals, as well as at our hospital; the results consistently indicated high cerebrospinal fluid (CSF) opening pressure. M. houstonense was detected in the CSF of the second hospital's lumbar puncture by metagenomic next-generation sequencing (mNGS) but was not identified at our hospital. The patient was discharged from our hospital after receiving non-tuberculous mycobacterium (NTM) treatment for 1 month according to the Chinese NTM guidelines. However, the patient died 20 days after discharge.Entities:
Keywords: Mycobacteria houstonense; Mycobacterium fortuitum group; central nervous system infection; next generation sequencing; rapidly growing mycobacteria
Year: 2022 PMID: 36119702 PMCID: PMC9475202 DOI: 10.3389/fneur.2022.908086
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.086
CSF findings.
|
|
|
|
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date | Dec 25, 2021 | Dec 29, 2021 | Jan 5, 2022 | Jan 12,2022 | Jan 14, 2022 | Jan 21, 2022 | Jan 24, 2022 | Jan 28, 2022 | Feb 7, 2022 | Feb 14, 2022 | |||
| Opening pressure (mmH2O) | 80–180 | >330 | 80–180 | >330 | >330 | >330 | 80–180 | 150 | >330 | >330 | >330 | >330 | >330 |
| Appearance | Yellow | Light yellow | Light yellow | Light yellow | Yellow, slightly turbid | Light yellow, transparent | Light yellow, transparent | Light yellow, transparent | Yellow, transparent | Colorless, transparent | |||
| Nucleated cell count(cells/ul) | 0–10 | 50 | 129 | 69 | 44 | 0–10 | 10 | 18 | 18 | 16 | 70 | 45 | |
| Proportion of mononuclear (%) | 95 | 94 | 95 | 91 | NA | NA | NA | NA | 94 | 96 | |||
| Microprotein (g/L) | 0.15–0.45 | 3.400 | 0.08–0.43 | 5.179 | 4.964 | 4.827 | 0.15–0.45 | 11.480 | 9.160 | 7.740 | 6.560 | 6.500 | 7.150 |
| CSF glucose (mmol/L) | 2.5–4.4 | 3.80 | 2.5–4.4 | 5.35 | 3.53 | 4.26 | 2.5–4.4 | 5.04 | 4.05 | 4.24 | 4.41 | 2.74 | 4.24 |
| Synchronous blood glucose (mmol/L) | 3.9–5.9 | NA | 3.9–6.1 | NA | NA | NA | 3.9–5.9 | 8.42 | 5.51 | 6.37 | 7.00 | 5.57 | 8.72 |
| CSF chloride ion (mmol/L) | 120–130 | 112 | 120–130 | 106.5 | 107.5 | 96.8 | 120–130 | 108 | 104 | 101 | 110 | 112 | 105 |
| Synchronous blood chloride ion (mmol/L) | 99–110 | NA | 90–110 | NA | NA | NA | 99–110 | 98.6 | 91.8 | 94.8 | 96.7 | 100.8 | 100.1 |
| IgG synthesis rate (mg/day) | 0–5.81 | NA | 0–5.81 | NA | NA | NA | 0–5.81 | NA | 251.70 | 34.99 | 124.84 | 301.92 | 146.00 |
| mNGS | NA | NA | NA | NA | Negative | Negative | NA | Negative | NA | ||||
| Acid-fast staining | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |||
| Mycobacterium culture | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |||
| Xpert MTB | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |||
| RT-PCR | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |||
| Culture of | NA | NA | NA | Negative | NA | Negative | Negative | NA | Negative | NA | |||
NA, not available.
Figure 4Clinical course, CSF findings, and antibiotic regimens for our case.
Figure 1MRI of the brain and cervical vertebra of our case. The axial section T1 weighted image showing hydrocephalus (arrow) (A). The sagittal section T1 weighted image showing hydrocephalus (arrow) (B). The axial section T2 weighted image shows hydrocephalus (arrow) (C). The sagittal section T2 weighted image showing hydrocephalus (arrow) (D).
Figure 2MRI of the brain and thoracic vertebra of our case. The sagittal section enhanced the image of the brain showing marked nodular enhancement under the pia mater (arrow) (A). The axial section and sagittal section of the thoracic vertebra showing marked nodular enhancement in the spinal cord (arrow) (B). The sagittal section of the thoracic vertebra showing marked nodular enhancement in the spinal cord (arrow) (C).
Figure 3MRI of the brain and lumbar vertebra of our case. The sagittal section and axial section of the lumbar vertebra showing marked nodular enhancement in the spinal cord at the level of the second lumbar vertebra (arrow) (A). The axial section of the lumbar vertebra showing marked nodular enhancement in the spinal cord at the same level in picture (A) (arrow) (B).